Chiasma Announces 48-Week Safety and Efficacy Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA® in Patients with Acromegaly

Stock Information for Chiasma Inc.

Loading

Please wait while we load your information from QuoteMedia.